H.C. Wainwright reiterates Kalvista stock Buy rating at $37 target By Investing.com

Kalvista reported $49.1M in global net product revenue for Ekterly over the eight months ending Dec 31, 2025, including $35.4M in Q4. The product launched in July 2025 and the company has 1,702 U.S. patient start forms (~20% of the U.S. patient population), supporting management's view of durable patient uptake and continued growth into year two. Multiple analysts reiterated or raised ratings and price targets (H.C. Wainwright $37, Stifel $42, Jefferies $38, Citizens $28, Leerink $22) and InvestingPro shows a consensus Strong Buy, indicating positive sell-side momentum that could move the stock in the near term.

Analysis

An oral, on‑demand HAE therapeutic that induces durable refill behavior shifts the entire channel economics away from clinic-administered injectables toward pharmacy-dispensed units. That rotation compresses revenue per treatment for incumbents even as patient-level utilization rises — a classic margin-versus-volume trade that disproportionately benefits companies with scalable small‑molecule manufacturing and specialty pharmacy distribution relationships.

Second‑order winners include specialty distributors and PBMs that can capture refill-driven recurring revenue and data flows; losers are physician practices and infusion centers that rely on buy‑and‑bill economics for on‑demand HAE care. Expect contracting dynamics to evolve: payers will push for pharmacy benefit placement and volume discounts while offering narrower formularies that favor the lowest net cost per treated attack.

Key risks that could reverse adoption are not clinical efficacy but access and supply: (1) aggressive step‑therapy or prior‑authorization requirements that blunt adoption over 3–12 months, (2) manufacturing or supply disruptions that create short‑term scarcity and revert patients to injectables, and (3) competitive oral entrants or biosimilars within 24–48 months that reprice the category. Watch next commercial cadence metrics (month‑over‑month refill rates, payer coverage wins, and days‑to‑ship for new starts) — they will drive 6–18 month share outcomes more than headline quarterly revenue.

From an execution angle, the upside is concentrated and binary over the next 12–24 months: continued durable refill growth and a string of formulary wins could re‑rate the equity materially, while payer pushback or a supply hiccup would cap upside and compress multiples quickly.

Key Decisions for Investors

• Long KALV via defined‑risk options: buy 18–24 month LEAP call spread (long lower strike / short ~30–40% higher strike) to capture adoption upside while capping premium outlay; target asymmetric upside of 2–4x vs max loss of premium. Hold horizon: 12–24 months and roll on clear payer/formulary wins.
• Tactical covered‑call sell after each quarterly print: sell 1–3 month OTM calls to harvest elevated post‑launch volatility if Qs confirm durable repeat usage; use proceeds to fund larger LEAP call exposure. Risk: limits upside between sale and expiry; reward: reduces carry and delta exposure to short‑term policy noise.
• Pair/relative‑value: small long KALV / short exposure to major injectable HAE incumbent (size ~50–75% notional of long) to isolate category share shift. Timeframe: 6–18 months. Rationale: isolates adoption vs macro biotech risk; primary downside is idiosyncratic news at the shorted incumbent.
• Event hedge: buy 3–6 month puts or a collar around core equity exposure ahead of major formularies/contract announcements to protect against sudden payer‑driven adoption pauses. Cost tolerances: accept up to ~3–5% of notional for near‑term insurance if exposure is material.